Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC). Talukder, R., Bakaloudi, D., Makrakis, D., Tripathi, N., Agarwal, N., Jindal, T., Koshkin, V. S., Johnson, J., Zakharia, Y., Brown, J., Rey-Cardenas, M., Castellano, D., Alva, A., Zakopoulou, R., Korolewicz, J., Drakaki, A., Barata, P. C., Grivas, P., Khaki, A. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001098050200507